A recent study published in Lancet used surgical data from 56 countries around the world to de� termine that globally there are over 230 million major surgical procedures undertaken annually. 1 Given that cardiac and pediatric surgery only ac� count for a minority of major surgical cases, it suggests that over 200 million adults undergo major noncardiac surgery annually, and sever� al million of these patients will suffer a major perioperative cardiovascular event (i.e., cardio� vascular death, nonfatal myocardial infarction, nonfatal cardiac arrest, or nonfatal stroke). 2 De� spite the magnitude of this public health problem, there has existed a paucity of adequately powered randomized controlled trials (RCTs) that have evaluated inter ventions that may lower the risk of a major cardiovascular event around the time of noncardiac surgery.
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Patients undergoing major noncardiac sur� gery experience high physio logical stress marked by a rise in catecholamines that result in an in� crease in heart rate and hence myocardial oxygen demand.
3,4 Several studies have shown an associa� tion between tachycardia and perioperative cardi� ac ischemia.
5-7 The increase in perioperative cate� cholamine levels also results in an increase in free fatty acids levels, which further increasing oxy� gen demand because free fatty acids require aer� obic meta bolism.
8 Additionally, free fatty acids can damage myocardial cell membranes and can precipitate serious arrythmias.
β�blockers attenuate the eff ects of increased cat� �blockers attenuate the effects of increased cat� echolamine levels, and this provided the physio� logical rationale that starting in the 1980s led authors to propose β�blockers as a potential preventive inter vention for major perioperative cardiovascular complications.
7,9 Paradoxical� ly, in the early 1970s β�blockers were stopped days before surgery as it was perceived that they could inhibit compensatory cardiovascular mech� anisms and thus predispose patients to serious cardiovascular outcomes. 10 In the 1990s 2 small RCTs 11,12 (312 patients in total) with concern� ing methodo logical limitations (i.e., unblinded, stopped early for unexpectedly large treatment effect in the setting of very few events, and failure to use the intention�to�treat principle) 13 , suggest� ed that β�blockers given around the time of non� cardiac surgery could prevent major cardiovascu� lar events. More recently, 2 moderate sized pe� rioperative β�blocker RCTs (1417 patients in to� tal), which avoided the biases of the prior small RCTs, did not show a benefit with perioperative β�blockers. 14, 15 Despite the limitations of the data, over a decade ago guideline committees started recommending perioperative β�blockers 16 , and even with the recent moderate sized RCTs dem� onstrating no benefit to perioperative β�blockade, guideline committees have continued to recom� mend that physicians give β�blockers to patients undergoing noncardiac surgery.
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Recently, we were part of a large inter national group that completed and published the first large perioperative β�blocker RCT. This trial was called the POISE (Perioperative Ischemic Evaluation) trial, and it was an RCT comparing the effect of ex� tended�release metoprolol succinate (metoprol� ol CR) with that of placebo on the 30�day risk of major cardiovascular events in patients with, or at risk of, atherosclerotic disease who were undergoing noncardiac surgery. 18 In POISE ran� domisation was conducted by a computerised
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are consistent with the prior high�quality tri� als. The only reason the signal of perioperative β�blockers increasing the risk of death and stroke was not obvious prior to POISE was that the for� mer trials were too small to demonstrate statis� tically significant results; however, their results were suggesting the same signal as POISE.
The POISE data offer insights into how periop� erative β�blockers can increase the risk of death and stroke. 20 In POISE more patients experienced clinically significant hypotension (i.e., a SBP <90 mmHg that someone had to do something about) in the metoprolol group than in the placebo group (625 [ We undertook post hoc multivariable analyses and determined population attributable risks (PARs), which represent the proportion of all outcomes attributable to the relevant risk factor if causality were proven. Clinically significant hy� potension had the largest PAR (37.3%) for death and the largest intraoperative/postoperative PAR (14.7%) for stroke. Further, perioperative stroke had a PAR of 8.0% and clinically significant brady� cardia had a PAR of 7.9% for the outcome death. Therefore, perioperative clinically significant hy� potension, bradycardia, and stroke, which periop� ertive β �blockers caused, potentially account for over 50% of the deaths demonstrated in POISE, and this explains how β�blockers increase a pa� tient's risk of death around the time of noncar� diac surgery. Although clinically significant hy� potension was an important predictor of periop� erative stroke our analysis explains less than half of the strokes. It is possible that more hypoten� sion occured that was clinically relevant but did not fulfill our definition even though it may have accounted for more of the strokes. The increase in clinically significant hypotension demonstrat� ed in POISE was also demonstrated in our previ� in POISE was also demonstrated in our previ� ous meta�analysis that included varying doses or other perioperative β�blockers (RR 1.27, 95% CI 1.04-1.56).
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The POISE results suggest that for every 1000 patients undergoing noncardiac surgery with a similar risk profile metoprolol CR would pre� vent 15 patients from suffering a myocardial in� farction, three from undergoing a cardiac revas� cularisation procedure, and seven from develop� ing new clinically significant atrial fibrillation.
The POISE trial also suggests that perioperative metoprolol CR would result in an excess of eight deaths, five patients suffering a stroke, 53 expe� riencing clinically significant hypotension, and 42 experiencing clinically significant bradycar� dia for every 1000 treated.
Although no patient would want to suffer a pe� rioperative myocardial infarction, we suspect that randomisation service that was available for in� vestigators to phone 24�hours a day. Patients, health�care providers, data collectors, and out� come adjudicators were blinded to treatment allocation. POISE included 8351 patients from 190 hospitals in 23 countries, and 8331 patients (99.8%) completed the 30�day follow�up. Analy� Analy� ses followed the intention�to�treat principle.
The dosing regimen in POISE was designed so that patients could get 200 mg of the study drug (i.e., metoprolol CR or matching placebo) during the first 24 hours. 18 Patients received 100 mg 2-4 hours prior to surgery and then 6 hours af� ter surgery another 100 mg. Patients thereafter received 200 mg of the study drug daily for 30 days. If a patient's heart rate was below 45 beats per minute (bpm) or their systolic blood pres� sure (SBP) <100 mmHg, their study drug was withheld until their heart rate or SBP recovered and then they restarted the study drug at 100 mg orally once a day. Patients whose heart rate was 45-49 bpm and SBP >100 mmHg delayed taking the study drug for 12 hours.
At the 30�day follow�up 244 (5.8%) of the me� toprolol patients and 290 (6.9%) of the placebo patients suffered the primary outcome -a com� posite of cardiovascular death, nonfatal myocar� dial infarction, and nonfatal cardiac arrest (haz� ard ratio [HR] for the metoprolol group, 0.84; 95% CI 0.70-0.99, p = 0.04). 19 We initially viewed the POISE findings of an in� creased risk of perioperative stroke and death from a perioperative β�blocker as surprising. However, when we updated our meta�analysis 20 the results of the 7 high�quality trials were con� sistent in demonstrating a higher risk of death with perioperative β�blocker therapy (relative risk [RR] 1.29, 95% CI 1.02-1.62, p = 0.03, I2 = 0%) 19 . Likewise, our updated meta�analysis of the 6 high�quality trials that reported a perioperative nonfatal stroke demonstrated a consistent find� ing of a higher risk of a nonfatal stroke with pe� rioperative β�blocker therapy (RR 2.16, 95% CI 1.26-3.78, p = 0.005, I2 = 0%). The same was also true for the outcome of nonfatal myocardial infarction in that the prior trials demonstrat� ed the same result as POISE when we included the 6 high�quality trials in an updated meta�anal� ysis; this meta�analysis demonstrated that peri� operative β�blocker therapy prevented nonfatal myocardial infarctions (RR 0.73, 95% CI 0.60-0.88, p = 0.01, I2 = 0%). Therefore, the POISE re� sults for death, stroke, and myocardial infarction patients would place more weight on avoiding an increased risk of death and stroke. Current pe� Current pe� rioperative guidelines that recommend β�blocker therapy to patients undergoing non�cardiac sur� gery should reconsider their recommendations in light of these findings.
POISE is the first large perioperative cardiovas� cular outcome trial, and it demonstrates the risk in assuming a perioperative β�blocker regimen has benefit without substantial harm. In POISE one in every 15 patients who participated suf� fered a cardiovascular death, nonfatal myocar� dial infarction, nonfatal cardiac arrest, or non� fatal stroke within the first 30�days. This burden of negative cardiovascular outcomes highlights the importance and need for large randomised trials in the perioperative setting to identify inter� ventions to reduce major perioperative cardio� vascular events. 
